710GO

710GO is a synthetic peptide drug candidate developed for the treatment of obesity. It acts as an agonist of the melanocortin-4 receptor (MC4R), leveraging the melanocortin system to induce weight loss. Preclinical studies in obese monkeys and rats have demonstrated that 710GO can achieve significant and sustained weight loss, with up to 11.7% reduction in body weight over 15 weeks, comparable to GLP-1 receptor agonists but without their common side effects such as nausea or vomiting. The drug also appears to minimize rebound weight gain after discontinuation and may promote healthier food choices by increasing preference for high-fiber, low-fat foods. Unlike current injectable therapies, 710GO is being developed as an oral medication, aiming for improved accessibility and patient compliance. The drug has shown a favorable safety profile in animal studies and is entering Phase I clinical trials under the development of Abisati, a spin-off from Endevica Bio[1][2][3][4][6].

Other names

Dual MC3R/MC4R agonist peptideKalohexis obesity peptide